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ABSTRACT
We recently reported on the pharmacokinetics in 14 cancer patients
of the 19-9 antibody radiolabeled with '"In. We have now repeated this
investigation in 18 cancer patients using the OC-125 antibody, in part to
compare the in vivo behavior of two murine monoclonal antibodies of the
same subclass administered as the F(ab'>2 fragments, by the same route
and at the same dose. As in the earlier investigation, 1 mg of fragments
was infused i.V., and organ quantitation was obtained for up to 72 h along
with frequent blood and urine samples for Chromatographie evaluation.
Analysis of urine showed that activity clearance by this route amounted
to 0.29%/h and consisted of labeled DTPA only in early samples and
metabolic products thereafter. Analysis of serum samples often showed
the presence of a high-molecular-weight species appearing within 24 h.
This species is probably due to antibody binding to circulating antigen,
although the percentage of circulating activity present as this species did
not correlate well with circulating antigen levels. As before, organ accu
mulation was greatest in the liver, although levels were significantly
reduced (12% compared to 20% of administered dose at 24 h, P < 0.01).
Plasma clearance was also significantly different: whereas the label in
the case of the OC-125 antibody showed one-compartment clearance
kinetics and remained in the plasma compartment, in the 19-9 case the
label diffused to a second, unidentified compartment.
INTRODUCTION
Reports on clinical investigations using radiolabeled antibod
ies for the diagnosis of cancer now appear with increasing
frequency (1). The majority of these studies have concentrated
primarily on imaging and, as such, are important to the evalu
ation of the efficacy of radioimmunoscintigraphy. Also impor
tant, however, is the determination of pharmacokinetic param
eters which may explain features within the images. Few clinical
studies have investigated pharmacokinetics by measuring blood
activity clearance curves and the rate of urinary excretion of
activity, by quantitation of activity levels in normal tissues and
in tumor and especially by the analysis of serum and urine
samples to determine the chemical forms of the radioactivity
present (2-5).
This laboratory recently reported on the results of a phar
macokinetic investigation in which the anti-colorectal tumor
antibody 19-9 was administered, labeled with indium-Ill
('"In), to 14 cancer patients (6). The 19-9 antibody is an IgGl
and was used in that study as the !â€¢"(;ib' )-fragment after coupling
via the cyclic anhydride of DTPA.3 Each patient was studied
following slow i.v. administration of 1 mg of fragments radio-
labeled with 1 to 2 mCi of '"In. Imaging was then performed
at regular intervals, and radioactivity levels in liver, spleen, and
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kidneys were determined. Affinity and gel filtration chromatog
raphy was performed on serum and urine samples.
One important observation ofthat study was the slow whole-
body clearance of radioactivity. The major route of excretion
was found to be to urine (0.26% injected dose per hour) which
by itself largely accounted for the observed 160-h whole-body
clearance half-time. At 24 h postadministration, 30% of whole-
body radioactivity was in liver, spleen, and kidneys, and 20%
was in blood. Since focal areas of radioactivity accumulation in
addition to the above organs were not apparent in the images,
the remaining 50% whole-body radioactivity was uniformly
distributed.
In the interest of determining these pharmacokinetic param
eters for a similar antibody, we have extended this investigation
to include the anti-ovarian tumor antibody OC-125. This anti
body was developed by Bast et al. by immunizing BALB/c mice
with human epithelial cells obtained originally from a patient
with serous papillary cystadenocarcinoma (7). Like 19-9, the
OC-125 antibody is an IgGl and was used in this study as the
F(ab')2 fragment after labeling in the identical manner with
'"In. Furthermore, the OC-125 antibody recognizes CA-125, a
high-molecular-weight (A/r > 200,000) glycoprotein (8), which,
like that recognized by the 19-9 antibody, is released to the
circulation (9).
The OC-125 antibody was administered to a total of 18
patients. As in the 19-9 study, each patient received 1 mg of
fragments, containing 1 to 2 mCi of "'In, by slow i.v. infusion.
In addition to the imaging of all patients (10), accumulation in
liver, spleen, and kidneys was quantitated in 16 patients by the
planar technique used in the 19-9 study. Serum and urine
samples were analyzed by open column and HPLC.
MATERIALS AND METHODS
The OC-125 antibody was produced by i.p. injection of hybridoma
cells into pristane-primed BALB/c mice. The OC-125 IgG was then
purified from filtered ascila fluid by Protein A-Sepharose (Pharmacia,
Piscataway, NJ) chromatography. The F(ab')2 fragments were produced
by digestion of the IgG antibody with 1% (w/w) pepsin in 37Â°C0.1 M
citrate, pH 4.2. Progress of the digestion was monitored by size exclu
sion HPLC analysis, and the digestion was terminated by neutralization
after about 18 h when the IgG peak disappeared. The F(ab')2 fragments
were purified by passing the digest through the Protein A-Sepharose
column to remove any undigested IgG or intact Fc antibody followed
by passage through a SuperÃ³se 6 filtration column (Pharmacia) to
remove other protein fragments. The resulting OC-125 F(ab')2 prepa
rations were routinely >95% pure by size exclusion HPLC analysis.
Prior to release for human use, each preparation was shown to be
sterile, apyrogenic, and free of murine retroviruses, Mycoplasma, and
potential toxic substances (BioSafe Systems, Inc., New Hyde Park, NY)
as required by the Food and Drug Administration.
Antibody coupling with DTPA, purification, and radiolabeling of the
fragments were performed as described previously (6). Three lots of
coupled fragments were used throughout this study; each was prepared
by coupling 20 to 30 mg of fragments using the cyclic anhydride of
DTPA (11) such that the average number of attached DTPA groups
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per fragment molecule was approximately one. Following purification
from free, unconjugated DTPA, the fragments were divided into sterile
vials such that each vial contained 1.0 mg of fragments contained in
200 to 800 n\ of 0.05 M bicarbonate buffer, pH 8.4. The vials were then
sealed and immediately frozen in liquid nitrogen for storage.
The immunoreactivity of the DTPA-coupled fragments was deter
mined using a competitive binding assay. Samples of a coupled (but
unlabeled) antibody fragment preparation were diluted in 0.1 M citrate
buffer containing 50% calf serum, pH 6.0, at antibody concentrations
between 200 Mg/ml and 0.001 fxg/ml. OC-125 IgG antibody, radioio-
dinated with '"I using Bolton-Hunter reagent (DuPont NEN Medical
Products, N. Billerica, MA) to a specific activity of 10 mCi/mg, was
then diluted to 100 ng/ml, and an equal volume was added to each
serial dilution such that the final concentration of iodinated antibody
in each was 50 ng/ml. Polyethylene beads (Precision Plastic Ball Co.,
Chicago, IL), which were previously coated with OC-125 IgG and then
CA-125, were incubated with 0.2-ml aliquots of each serial dilution in
duplicate for 16 h at room temperature. The beads were then washed 3
times with distilled water and counted in a gamma-well counter. Un
coupled OC-125 F(ab')2 was also assayed as a positive control.
A chromogenic I inni Ius Amebocyte Lysate pyrogen test (QCL-1000;
Whittaker M. A. Bioproducts, Walkersville, MD), general safety test
(21CFR610.11), and sterility tests (21CFR610.12) were performed on
one vial of each lot selected at random.
Before each patient study, a vial was allowed to warm to room
temperature, and 1 to 2 mCi of research-grade '"In (DuPont NEN
Medical Products), which had previously been made 0.25 M in sterile
sodium acetate at pH 5.0, was added with a sterile plastic pipet tip.
The contents of the vial were then diluted with about 0.2 ml of saline
and drawn into a 3-ml syringe along with an additional 2.0 ml of sterile
saline. Several aliquots of the preparation were removed for radioactiv
ity standards and for the analysis of radiochemical purity. The latter
was determined by size exclusion HPLC usually using a single 7.5- x
300-mm TSK 250 column (Bio-Rad Laboratories, Richmond, CA) and
0.1 M phosphate, pH 7.0 eluant.
Eighteen patients with documented malignancies were studied. Me
dian age was 54 with a range of 36 to 71. Ten patients received
chemotherapy (Adriamycin, cisplatin, and occasionally Cytoxan) prior
to this study. All patients signed informed consent and were studied
with the approval of the Food and Drug Administration (IND BB 1863)
and the appropriate institutional review committees. Patients 8 and 9
were readministered the labeled antibody after 10 and 4 mo, respec
tively.
Each patient received by slow i.v. infusion (30 to 45 min) approxi
mately 150 ml of saline containing 1.0 mg of fragments radiolabeled
with 1 to 2 mCi of "'In. One preadministration and several postadmin
istration blood samples were usually obtained along with a complete
urine collection throughout the study (usually 72 h). In most cases,
quantitation of radioactivity in liver, spleen, and kidneys was deter
mined at several times postadministration by planar imaging on a
Picker International DynaScan SPECT camera equipped with a me
dium-energy collimator as described previously (6).
Several blood samples were collected in heparinized tubes, and the
percentage of radioactivity bound to formed elements was determined
by counting in a gamma-well counter after repeat rinsing and centrif-
ugation. Most blood samples were collected in red-top vacutainers and
were allowed to clot to provide serum for analysis.
In addition to counting in a well counter along with a standard of
the injectate, all serum samples were analyzed for CA-125 levels by
radioimmunoassay (Centocor, Inc., Malvern, PA) after decay of '"In.
Most of the serum samples obtained in this study were also analyzed
for affinity using the CA-125-coated beads described above, to deter
mine the relative percentage of radioactivity in serum which is antibody
bound. Since binding of labeled antibody, even in the absence of serum,
is not quantitative in this assay, the trends in binding, rather than
absolute binding, among serum samples collected at different times
were examined.
In a search for radiolabeled species in serum of high molecular
weight (possibly signifying antigen-antibody or human anti-mouse re
sponse), serum samples were also analyzed by gel filtration chromatog-
sponse), serum samples were also analyzed by gel nitration chromatog-
raphy. Initially this was accomplished by open column chromatography
using a 1- x 170-cm Sephadex G200 column (flow rate, 5 ml/h) and
saline eluant. More recently size exclusion HPLC was used for this
purpose using a single 7.5- x 300-mm TSK 400 column (Bio-Rad) and
0.1 M phosphate buffer, pH 7, eluant (12). Fractions were collected and
counted in a well counter along with a standard of the injectate. Cation
exchange HPLC was also performed on serum samples to measure the
percentage of radioactivity bound to transferrin. A single 7.5- x 75-mm
SP 5PW cation exchange column (Waters Associates, Milford, MA)
was used with gradient elution from 0.02 M sodium acetate, pH 5.0, to
0.5 M sodium sulfate, 0.02 M tris hydrochloride, pH 8.0, in 30 min.
Samples of urine were analyzed by gel filtration chromatography and,
occasionally, by aniÃ³nexchange chromatography to help identify the
radiolabeled species in urine. Initially, a 1- x 150-cm column of Seph
adex G50 (flow rate, 40 ml/h) was used with saline eluants, while more
recently a single 7.5- x 300-mm 1-60 size exclusion HPLC column
(Waters) was used with 0.1 M phosphate, pH 7, eluant. A single 7.5- x
75-mm DEAE-anion exchange HPLC column (Waters) was also used
with gradient elution from 20 mM tris buffer, pH 8.5, to 20 mM tris
buffer, 0.5 M sodium chloride, pH 7.0, in 30 min. As in the case of
serum, urines were analyzed by collecting fractions for counting in a
well counter.
The serum clearance curves obtained by counting aliquots of each
serum sample were analyzed by the AUTOAN program (13) to obtain
initial estimates of pharmacokinetic parameters and to determine
whether the data were best fit by a one- or two-compartment model.
The data were then fitted to the model using NONLIN84 (Statistical
Consultants, Lexington, KY) weighted by the square of the reciprocal
of serum concentration. The model parameters were used to calculate
the intercompartmental rate constants by conventional methods (14).
Noncompartmental parameters, CI, MRT, Vc, and Vdts,were calculated
using the area under the clearance curve and the area under the first
moment curve (13). The identical analysis was performed on serum
clearance curves obtained in the 19-9 study.
RESULTS
The results of all tests to which the antibody was subjected,
both before and after coupling and labeling, demonstrated that
the injectate was safe for human use. Three lots of DTPA-
coupled OC-125 fragments were used in this investigation. The
first (used in Patients 1 to 7) contained an average of 1.2 DTPA
groups per fragment, while for the second (used in Patients 8
to 14) and third (used in Patients 15 to 18), this value was 0.8
and 0.9, respectively. The percentage of dimeric species (gen
erated during conjugation with DTPA) was 20, 5, and 6% for
the three lots, respectively. These dimeric species were not
removed in part because no decrease in immunoreactivity was
observed for preparations of DTPA-conjugated fragments of
OC-125 with up to 23% dimer by the above competitive binding
assay.4 Fig. 1 presents the results of the competitive binding
assay performed on the first lot of DTPA-conjugated antibody
which demonstrate that the immunoreactivity of this product
was not detectably altered from that of the antibody before
conjugation.
Following radiolabeling, radiochemical purity, defined as the
fraction of activity present as labeled antibody, averaged 98 Â±
7% (SD, n = 18) by HPLC analysis. The absence of radiocol-
loids and radiolabeled aggregates in these labeled fragment
preparations was demonstrated by the absence of radioactivity
voiding in the HPLC analysis, by recoveries in this analysis
averaging 92 Â±7% (SD, n = 18) and by the absence of detectable
radioactivity removed by centrifugation at 110,000 x g for 2 h.
Analysis of Serum Samples. The analysis of whole blood
showed less than 3% of the radioactivity on formed elements
4 Unpublished observations.
6112
PHARMACOKINETICS OF "'In-LABELED ANTIBODIES
20 -
P
I
123456
-LOG ANTIBODY CONCENTRATION (mg/ml)
Fig. 1. Results of competitive binding assay in which uncoupled (O) and
DTPA-coupled (â€¢)F(ab')2 fragments of OC-I25 were each placed in competition
with radioiodinated OC-125 IgG for antigen bound to beads (see text). Points,
mean counts per minute on beads compared with the negative log of unlabeled
antibody concentrations; bars, range of repeat measurements (n = 2).
Table 1 Preadministration circulating CA-125 antigen levels, percentage of
serum activity present in a high-molecular-weight species at 19 to 24 h post-
antibody administration, percentage of administered activity in liver at 24 h
postadministration, plasma clearance, and volume of distribution at steady state
obtained in patients administered '"In-labeled OC-125 (F(ab')Â¡(a partial list)
Patient123467910II129f17188'Preadminis
tration
CA-125(units/ml)"NA*94042302220391414431>500920Serum
high-
molecular-wt
species(%)2471643311596139600022Liver
activity
at 24 h
(% of in
jectedose)NA16.510.7NA11.29.211.214.417.512.39.110.512.116.2CI
(li-
ters/h)0.08380.06390.02470.03880.03790.02400.07110.04950.09680.0897NA0.04930.03930.1130V,.2.23.01.71.32.11.22.72.92.92.3NA2.61.73.4
" Each unit equals 0.015 ng of antigen.
* NA, not available.
c Repeat study.
at all time points. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis with autoradiography of labeled OC-125 and
19-9 antibody incubated at 37Â°Cin serum for up to 48 h showed
only a few percentages of Fab' fragments present in both cases
at all time points.
The analysis of preadministration serum samples for CA-125
provided the values presented in Table 1. Analysis of postad
ministration serum samples showed that most CA-125 levels
were below detectable limits. The exceptions are Patient 11, in
whom the concentration immediately dipped below the pread
ministration level and was not reestablished for more than 24
h, and Patient 14, in whom all samples showed the same value
of 200 to 400 units/ml. The behavior of circulating antigen in
only these two patients approximates the behavior observed
consistently in the 19-9 investigation.
The percentage of radioactivity in serum which binds to the
CA-125 derivatized beads is presented in Fig. 2 against time
postadministration. In each study, an aliquot of the injectate,
diluted in serum from a normal volunteer to approximately the
same labeled antibody concentration as in the initial patient
serum, was also analyzed. Binding of the control serum was
0.25
TIME (Hours)
Fig. 2. Percentage of radioactivity in serum which binds to anti-OC-125
affinity beads compared with time following administration of labeled antibody
(semilog scale). Patients identified by number. Points, mean of repeat measure
ments (n = 2 to 3).
approximately that of the initial patient serum in all cases.
In the 19-9 investigation, a rapid decrease was observed in
the percentage of serum radioactivity which bound to the affin
ity column, followed by an equally rapid increase such that
initial values were reestablished in about 1 h postadministra
tion. This trend was not as dramatic in the present study as
both the decline and rise were less pronounced in general and
occurred more slowly, taking about 20 h. As in the 19-9 case,
decrease in binding is most likely due to the formation of
antigen-antibody complex which cannot bind to the affinity
Chromatographie medium whereas the subsequent increase in
binding results from the clearance of these species from circu
lation.
After about 24 h postadministration, a second decline is
evident in the figure. A similar decline, estimated at 9% per
day, was observed in the 19-9 study and was attributed to
transcomplexation of the '"In from antibody to circulating
transferrin. Estimates of the rate of "'In transcomplexation in
serum for a number of proteins conjugated with DTPA vary
from 2 to 10% per day (15). The results presented in the figure
may be used to estimate that, in the case of the OC-125
antibody, this decline averaged 16 Â±11% per day. This value
is, therefore, in overall agreement with previous studies and
suggests that the rate of transcomplexation is independent of
the labeled protein.
A more accurate measurement of the rate of transcomplexa
tion was provided by analysis of serum samples on a cation
exchange HPLC column. Several radiochromatograms ob
tained on this column are presented in Fig. 3. Analysis in this
way of the native, unconjugated antibody fragment with UV
detection showed several peaks, most likely resulting from the
presence of several species differing in the degree of glycosyla-
tion. These multiple peaks are also apparent in the radiochro-
matogram of the injectate shown in the figure. These peaks
persist in serum however, an additional peak, not present in the
injectate and due to '"In-transferrin, is also apparent Â¡nserum.
The rate with which this peak increases provides a value of 6%
per day for the rate of transcomplexation.
The percentage of serum radioactivity present as a high-
molecular-weight species (i.e., eluting substantially before the
radiolabeled fragment on both open column G200 and TSK
400 HPLC) at 19 to 24 h postadministration is also listed in
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Fig. 3. Several radiochromatograms obtained by the analysis of the indicated
samples on an SP 5PW cation exchange HPLC column. Analysis of three serum
samples shows the presence of one peak, not present in the injectate, which
coelutes with '"In-labeled transferrin. The percentage of serum radioactivity
present as labeled transferrin is seen to increase with time postadministration.
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Fig. 4. Radiochromatograms obtained by size exclusion HPLC analysis of
radiolabeled OC-125 fragments and of three sera from one patient administered
the labeled fragments. With increasing time postadministration, the percentage
of radioactivity present in serum as labeled fragments is found to decrease relative
to radioactivity present in a high-molecular-weight form.
Table 1. The speed of HPLC permitted the analysis of several
serum samples from each patient. As shown in Fig. 4, the
percentage of activity in a high-molecular-weight form was thus
found to increase in one patient from about 17% initially (i.e.,
approximately 45 min after the start of antibody infusion) to
39% at 21 h postadministration. A similar slow accumulation
of radioactivity in a high-molecular-weight species has been
reported for this antibody and attributed to antigen-antibody
complex formation (16).
Analysis of the serum clearance curves provided the mean
values for Cl, MRT, Vc, and Vdsslisted in Table 2. Also in the
table are the values obtained by identical analysis of the 19-9
clearance curves (6) not previously reported. Statistically sig
nificant (P < 0.05) differences in the pharmacokinetic measure
ments were seen in Cl, Vdss, and MRT by a pooled / test
(MINITAB Statistical Package, University Park, PA). The
volume of the central compartment is statistically identical for
both antibodies at about 2.4 liters, approximately the plasma
volume of the patients. However, the volume of distribution at
steady state is significantly larger for the 19-9 antibody, sug
gesting that the label in this case only diffuses from plasma.
Serum clearance of radioactivity calculated from the observed
mean pharmacokinetic parameters assuming administration of
the same radioactive dose for both antibodies is illustrated in
Fig. 5.
Analysis of Urines. As in the case of the 19-9 study, radio
activity released to urine following administration of the OC-
125 antibody was slow but steady in all patients, averaging
0.29% of the injected dose per hour. This value is essentially
identical with the 0.26% per hour value observed in the 19-9
investigation. Furthermore, G50 chromatography and 1-60
HPLC analysis of urine showed identical radioactivity profiles
to those observed in the 19-9 study. Two peaks were observed
with the peak at longer retention time decreasing in intensity
relative to the peak at the void volume from early to late urine
collections. The urine samples were also analyzed by DEAE-
anion exchange chromatography. Fig. 6 shows typical radi
ochromatograms obtained in this manner in the analysis of
three urine samples from one patient. Activity in the earliest
urine collection coelutes with "'In-DTPA and is most probably
present largely as labeled free DTPA (since a small amount of
this species is in the injectate), whereas in later collections
activity is clearly present in another chemical form(s) as shown
by the shift in retention time.
Organ Quantitation. Liver radioactivity levels are shown
graphically in Fig. 7 in the percentage of the administered
activity, corrected for decay, compared with time postadminis
tration. Trends apparent in the figure are similar to those
observed in the 19-9 study in that liver levels are high initially,
possibly reflecting blood pool in this organ, but do not decrease
significantly throughout the study. As in the 19-9 study, a large
variation in liver accumulation is apparent among patients
receiving the OC-125 antibody. Values for spleen and kidneys
remained essentially constant throughout each study, although
at much lower levels than those of liver.
A noteworthy difference with the 19-9 investigation is the
lower radioactivity levels in liver, spleen, and kidneys. A com
parison of these values obtained in both studies is presented in
Table 3.
In a search for correlations between liver activity accumula-
Table 2 Analysis of serum clearance curves obtained in the study of the 19-9 and the OC-125 antibodies
Values for CI, MRT, half-times of serum clearance, Vc, and Vdâ€žare listed along with the significance of the difference in these values between the two antibodies.
Antibody19-9
(/i = 7)
OC-125 (n=13)SignificanceCl
(liters/h)0.13
Â±0.05Â°
0.056 Â±0.025P
< 0.005MRT
(h)28
Â±1044
Â±14P
< 0.05ty,a
(h) tv*(h)S.I
Â±3.8 27 Â±6.6
21 Â±8.6NS*Vc2.5
Â±1.0
2.3 Â±0.7NSVta3.5
Â±1.52.2
Â±0.6P
<0.05â€¢
Mean Â±SD.
* NS, not significant.
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Fig. 5. Serum radioactivity clearance curves for both the 19-9 and OC-125
antibodies calculated from pharmacokinetic parameters derived from clearance
measurements. Curves are calculated for the same administered radioactivity;
nevertheless the 19-9 radioactivity levels are lower as label diffuses from the
plasma space.
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X T-24-48 MRS
Z
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Fig. 6. Radiochromatograms obtained by aniÃ³nexchange HPLC analysis of
three urine samples obtained from one patient. With increasing time postadmin
istration the percentage of radioactivity in urine which coelutes with labeled free
DTPA decreases, while radioactivity at the void volume increases.
tion at 24 h postadministration and the results of other meas
urements, a linear regression analysis for two components was
conducted (MINITAB) to assess the relationship among liver
radioactivity at 24 h, preinjection CA-125 serum levels, radio
activity in serum at 19 to 24 h postadministration in a high-
molecular-weight form, Cl, and Vds.,.The analysis was per
formed on the mean values of these measurements obtained in
the OC-125 and 19-9 study, but in the latter case without the
inclusion of high-molecular-weight serum values. Significance
(P < 0.05) was found in the case of OC-125 antibody for liver
accumulation and Cl. Significance was not found in the 19-9
case.
Tissue Counting. Among the patients administered the OC-
125 antibody, three underwent surgery before radioactivity in
tissues decreased to background levels. In one patient a perito
neal nodule was removed at 3 days postadministration and
found to contain a metastatic poorly differentiated adenocarci-
noma with features consistent with an ovarian primary. Radio
activity in this tissue was 2 times background at 0.0083% of
the injected dose per gram. Only normal tissues were obtained
from the second patient at 4 days postadministration. Mean
40 60 80
TIME (Hours)
Fig. 7. Radioactivity in liver presented as percentage of administered '"In
(corrected for decay) compared with time after administration of labeled antibody.
Patients identified by number. One curve has been extended to a data point off
scale. Radioactivity levels obtained following a second administration of labeled
antibody are indicated by an asterisk.
Table 3 Results of quantitalion of liver, spleen, and kidneys at 24 h
postadministration obtained in the study of the 19-9 and OC-125 antibodies
along with the significance of the difference in these values between the
two antibodies
Antibody19-9
(n= 10)
OC-125(n=13)SignificanceLiver20
Â±8Â°
12Â±3/><0.01Spleen1.7
Â±1.1
1.1Â±0.6NS*Kidneys7.3
Â±5.3
3.6 Â±2.0NS
* Mean Â±SD of the percentage of injected dose.
* NS, not significant.
Fig. 8. Series of whole-body posterior images obtained at 1 (.11. 24 (Hi. and
48 (C) h postadministration with '"In-labeled OC-125 fragments. An aliquot of
the injectate was placed near the shoulder during each acquisition.
radioactivity in these tissues was 0.002% injected dose per
gram. Finally, a supraclavicular lymph node containing recur
rent adenocarcinoma was removed from a patient at 18 days
postadministration which contained 0.031% of the injected
dose per gram. Although normal tissue was not removed, it
may be estimated from the previous two patients that, in this
case, the tumor/normal tissue ratio exceeded 15.
Imaging. Fig. 8 illustrates the biodistribution of '"In follow
ing administration of the labeled OC-125 antibody. Three
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whole-body images obtained at 1, 24, and 48 h postadministra
tion are shown of the same patient. These images are typical of
those obtained in patients thought to be disease free, and they
show early and persistent high activity levels in liver, spleen,
and kidneys. Blood activity is still evident even at 48 h, espe
cially in the blood pool of the heart. Very little activity is
apparent in bone marrow or in gut.
DISCUSSION
Since an object of this investigation was to compare the in
vivo pharmacokinetic properties of two antitumor antibodies,
the antibodies were selected to be as similar as possible. Thus,
both the OC-125 and 19-9 are of the IgGl subclass and are
directed against shed antigen. Both were used in these investi
gations as the DTPA-coupled F(ab'>2 fragments radiolabeled
with '"In in the identical fashion. Finally, both were adminis
tered by i.v. infusion at a loading dose of 1 mg of protein and
1 to 2 mCi of radioactivity.
Several noteworthy similarities are apparent in the results of
these studies. Despite a greater tendency toward dimer protein
formation during DTPA conjugation, the immunoreactivity of
the OC-125 antibody, like the 19-9 antibody, was unaffected by
the conjugation, as determined by competitive binding. Size
exclusion HPLC and ultracentrifugation also showed no evi
dence of radiocolloids or other labeled aggregates. Furthermore,
an estimate of the rate of in vivo transcomplexation of '"In
from antibody in serum to transferrin (6%/day) is consistent
with that (9%/day) obtained for the 19-9 antibody.
Since the antigen CA-125 is shed into the circulation, the
presence of circulating activity in a high-molecular-weight form
signifying antigen-antibody complex formation was expected
and, as in the 19-9 case, was most likely observed (Fig. 4). The
extent to which these species formed at 19 to 24 h postadmin
istration was, however, variable and does not correlate with
circulating CA-125 levels. Also in agreement with the 19-9
study, liver activity levels reached maximum values soon after
antibody infusion and did not decline thereafter.
As in the 19-9 case, the only major route of whole-body
elimination of radioactivity was via the kidneys, and essentially
identical elimination rates into urine (0.29 compared to 0.26%/
h) were observed. In both cases, elimination was rapid within
the first 4 to 8 h, due most likely to glomerular filtration of the
small amount of '"In-labeled DTPA in the injectate. This
suggestion is supported by Chromatographie analysis of urine
samples which shows the presence of this species only in early
samples. However, elimination by this route continues there
after at a steady rate, and Chromatographie evaluation of later
samples shows the presence of species distinct from labeled
DTPA which are most probably metabolic products.
Although these similarities in in vivo behavior of the two
antibodies are important, it may be the differences which are
most significant. From the point of view of radioactivity accu
mulation in liver, often considered to be problematic in the use
of "'In-labeled antibodies, the OC-125 antibody showed signif
icantly decreased liver levels at 24 h postadministration with
respect to those observed with 19-9 (12% compared to 20%).
A similar decrease was observed for spleen and kidneys as well
(Table 3). The reason for these decreased levels is not apparent
but may be related to differences also observed in plasma
clearance. When administered as the labeled OC-125 antibody,
"'In is cleared monoexponentially with Vdssequal to the Vc
which, in turn, is roughly equal to the plasma volume. Appar
ently this labeled antibody does not diffuse appreciably from
the plasma space. In the case of the 19-9 antibody, by contrast,
'"In followed a biexponential clearance curve with an apparent
volume of distribution at steady state significantly larger than
the initial volume of distribution. In this case, the label is
diffusing from plasma and appears to distribute within a com
partment with a volume of approximately 1.4 liters. This com
partment has not been identified; nevertheless, it must be uni
formly distributed throughout the whole body; otherwise radio
activity in the compartment (approximately 50% of the injected
dose at 24 h) would appear in the whole-body images as one or
more areas of increased activity. This radioactivity is not bound
to formed elements in blood, and it is unlikely that the com
partment represents either total body water, extracellular, or
intrinsic fluid since these volumes are reported to be approxi
mately 40 to 45,13 to 16, and 10 to 13 liters for a 70-kg subject
(17). This analysis is, however, based only on radioactivity levels
in serum and is therefore complicated by the presence in serum
of at least two chemically distinct forms of '"In: radiolabeled
antibody and a radiolabeled high-molecular-weight species,
most likely antigen-antibody complex. If the latter clears more
slowly from serum compared to labeled antibody, the result will
be a decrease in the apparent clearance rate. Since the volume
of distribution has been calculated using the area under the
clearance curve, a decreased clearance can have the effect of
lowering the apparent volume of distribution. In the absence of
information on the separate rate of clearance for each labeled
species, a volume of distribution for the antibody itself cannot
be calculated and, thus, an anatomical location for the second
compartment cannot be identified.
In summary, the properties of the "'In radiolabel itself were
found to be independent of whether attached to the 19-9 or
OC-125 antibodies. Although certain similarities were observed
in the in vivo behavior of the antibodies, the differences in
pharmacokinetics for two similar antibodies administered in
identical fashion were surprising. Decreased liver levels ob
served for the OC-125 antibody suggest that further decreases
in these levels may result from the use of other antibodies with
even more favorable pharmacokinetics. It is possible that the
selection of new antibodies for tumor localization should be
made not only on the basis of affinity and specificity but on
pharmacokinetic properties as well.
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